Global Causes of Death to

We are sorry but this premium report expired!

This market research, not available anymore on the publisher's website, was withdrawn from our database.

To get an alternative report, you can either :

  • Have a look at the list of documents hereafter
  • Launch a new search below

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

DOWNLOAD THESE REPORTS NOW!

Cardiometabolic Drug News FEBRUARY 2015

Cardiometabolic Drug News FEBRUARY 2015

  • $ 1 114
  • Industry report
  • by Espicom Business Intelligence
  • February 2015
  • 13 pages

Industry Trend Analysis - Afrezza's US Launch Will Test Appetite For New Insulin Delivery Systems Industry Brief - Merck Repatriates Diabetes/Thyroids Portfolio In Russia Industry Brief - Hua Raises Funds To Start Phase II Trials Industry Brief - FDA Approves First-In-Class Glyxambi For Adults With Type ...

Industries: Pathology | Countries: South Korea, Switzerland, Russian Federation, Israel, United States, United Kingdom

Bukwang Pharmaceutical Co., Ltd. (Symbol:003000) SWOT Analysis, Strategy, Revenues and Profits

Bukwang Pharmaceutical Co., Ltd. (Symbol:003000) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Bukwang Pharmaceutical Co., Ltd. SWOT Analysis report provides you ...

Industries: Pathology | Countries: South Korea

Oscotec Inc. (Symbol:039200) SWOT Analysis, Strategy, Revenues and Profits

Oscotec Inc. (Symbol:039200) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Oscotec Inc. SWOT Analysis report provides you a strategic analysis ...

Industries: Pathology | Countries: South Korea

Samjin Pharmaceutical Co., Ltd. (Symbol:005500) SWOT Analysis, Strategy, Revenues and Profits

Samjin Pharmaceutical Co., Ltd. (Symbol:005500) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. Samjin Pharmaceutical Co., Ltd. SWOT Analysis report provides you ...

Industries: Pathology | Countries: South Korea

Pharmaxis Limited (PXS) - Financial and Strategic SWOT Analysis Review

Pharmaxis Limited (PXS) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

Summary Pharmaxis Ltd. (Pharmaxis) is a pharmaceutical company. The company develops products for diagnosis and treatment of chronic respiratory and immune disorders. It offers products such as include Aridol, and Bronchitol. Pharmaxis's Aridol is a lung function test and is to assist physicians in an ...

Industries: Pathology | Countries: Australia, South Korea

Green Cross Cell Corporation (031390) - Financial and Strategic SWOT Analysis Review

Green Cross Cell Corporation (031390) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

Summary Green Cross Cell (Green Cross), formerly Innocell Corporation, is a pharmaceutical company. The company develops immune cell treatment drugs and the storage of immune cells. It offers Immuncell-LC, an anti-cancer immune therapeutic drug to general hospitals and cancer centers for the treatment ...

Industries: Pathology | Countries: South Korea

Daihan Pharm Co.Ltd. (023910) - Financial and Strategic SWOT Analysis Review

Daihan Pharm Co.Ltd. (023910) - Financial and Strategic SWOT Analysis Review

  • $ 300
  • Company report
  • by Global Data
  • January 2015
  • 25 pages

Summary DAIHAN PHARM CO.LTD. (Dai Han) is a pharmaceutical company. The company manufactures and supplies infusions, injections, contrast media, and quasi drugs. Its product portfolio includes iohexol, dextran 40 dex, daihan d-mannitol, hexrosyl injection, multiflex peri, saeronamin, ultrasol, nephrisol, ...

Industries: Pathology | Countries: South Korea

Hanmi Pharmaceuticals, Co. Ltd. (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Hanmi Pharmaceuticals, Co. Ltd. (128940) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • by Global Data
  • December 2014
  • 49 pages

Summary Hanmi Pharmaceuticals, Co. Ltd. (Hanmi Pharma) is a pharmaceutical products manufacturer. The company manufactures and supplies prescription drugs and over-the-counter (OTC) drugs. Its prescription drugs include antibiotics, osteoporosis, liver supplements and antiemetics. Hanmi Pharma offers ...

Industries: Pathology | Countries: South Korea

CUREXO, INC. (Symbol:060280) SWOT Analysis, Strategy, Revenues and Profits

CUREXO, INC. (Symbol:060280) SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • by Global Data
  • November 2014
  • 25 pages

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days. CUREXO, INC. SWOT Analysis report provides you a strategic analysis ...

Industries: Pathology | Countries: South Korea

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014

  • $ 2 000
  • Industry report
  • by Global Markets Direct
  • October 2014
  • 46 pages

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014 Summary Global Markets Direct's, ‘Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014', provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome)'s therapeutic pipeline. This ...

Industries: Pathology | Countries: World, South Korea, United States

24/7 Customer Service

You can call our customer service 24 hours a day / 7 days a week

  • +1 718 303 2019

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.